Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.58 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30045411 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1 | |
| SCHEMBL23579456 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1 | |
| SCHEMBL26601574 | 0.85 | GPR119 (0.43) | GPR119 | |
| SCHEMBL26601507 | 0.84 | GPR119 (0.48) | GPR119ALOX5APFEN1 | |
| SCHEMBL30624444 | 0.84 | GPR119 (0.48) | GPR119ALOX5APFEN1 | |
| SCHEMBL21191755 | 0.84 | GPR119 (0.55) | GPR119PIK3CD | |
| SCHEMBL29058721 | 0.84 | ALOX5AP (0.51) | GPR119ALOX5APFEN1 | |
| SCHEMBL22597531 | 0.83 | GPR119 (0.50) | GPR119 | |
| SCHEMBL22597585 | 0.83 | GPR119 (0.50) | GPR119 | |
| SCHEMBL29483697 | 0.83 | GPR119 (0.50) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282795-A1 | EGFR Inhibitors in cancer treatment | CELYN THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4511376-A2 | EGFR INHIBITORS IN CANCER TREATMENT | Celyn Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282795-A1 | EGFR Inhibitors in cancer treatment | EGFR, ERBB2, ERBB4 | GPR119 1434/4885ALOX5AP 3300/4885FEN1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.